Final dividend 2019 Royal DSM
DSM declares a dividend for the financial year 2019 of €2.40 per ordinary share.
08 May 2020
DSM at a glance
Overview of our business & performance
2018 Integrated Annual Report
Strong progress on People, Planet and Profit
Why invest in DSM?
Our investor proposition
Growth & Value: Purpose-led, Performance-driven
Our ambitious financial targets
- at-a-glance
- annual-report-2018
- why-invest
- strategy
Key facts & figures
Royal DSM is a global purpose-led, science-based company in Nutrition, Health and Sustainable Living. DSM’s purpose is to create brighter lives for all. With its products and solutions DSM addresses some of the world’s biggest challenges whilst creating simultaneously economic, environmental and societal value for all its stakeholders; customers, employees, shareholders, and society-at-large. DSM delivers innovative solutions for human nutrition, animal nutrition, personal care and aroma, medical devices, green products and applications, and new mobility and connectivity. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 23,000 employees. The company was founded in 1902 and is listed on Euronext Amsterdam.
A broad, global nutrition business and a focused, high-quality, specialty materials portfolio
~€10b
Sales per year
~70%
In nutrition
~20%
Sales from innovation
~23,000
Employees
- NUTRITION
- MATERIALS
Nutrition
We provide nutritional solutions for animal health and human well-being, serving the global feed, food & beverage, pharmaceutical, infant nutrition, dietary supplements and personal care industries.
Animal Nutrition & Health
2019
Sales: ↑€2,892 (2018: €2,749)
Organic Growth: ↑4%
Volume Growth: ↑2%
Price Growth: ↑2%
Human Nutrition
2019
Sales: ↑€2,046 (2018: €1,989)
Organic Growth: ↓1%
Volume Growth: ↑2%
Price Growth: ↓3%
Sales1
€6,028m
Adjusted EBITDA1
€1,250M
Adjusted EBITDA Margin1
20.7%
1) Underlying business, net of temporary vitamin effect
Materials
Advanced and high-performance materials for the electrical & electronics, automotive, packaging, consumer goods, life protection, transportation and telecom industries.
Sales
€2,746M
Adjusted EBITDA
€509M
Adjusted EBITDA Margin
18.5%
Key facts 2019
We're a global leader in nutrition, active over full value chains serving local markets in 60 countries. Our unique and diverse portfolio combined with transformatinal capability enable us to the capability to respond to market needs, communities and people.
People 2019
Workforce
22,174
Year end 2019, excl. affiliates
Engagement
74%
Employee engagement favorable score with 92% response rate (76% in 2018)
Gender ratio
28/72
Female/male ratio (28/72 in 2018)
Safety
0.28
Frequency Index of Recordable Injuries per 100 employees & contractors (0.33 in 2018)
Female exec.
20%
Female executives (19% in 2018)
Planet 2019
Greenhouse gasses
~17%
GHG scope 1 + 2 reduction –
cumulative structural
improvement1 versus ~8%
in 2018 (baseline 2016)
Purchased electricity
50%
Purchased electricity
from renewable sources
versus 41% in 2018
Energy Efficiency
2.3%
Energy efficiency
improvement year on year
versus 1.4% in 2018
1) We estimate that the effect of the underlying cumulative structural improvements in absolute GHG emissions was approximately 17% and 8% in 2019 and 2018 respectively, versus the 2016 baseline. The total cumulative absolute reduction was 25% and 18% respectively, versus the 2016 baseline.
Profit 2019
Net
Sales
€9,010m
2018: €8,8521
Adjusted EBITDA
€1,684m2
2018: €1,5321
Adj EBITDA
Growth
+10%2
versus 20181
Adj net operating
free cash flow
€8012
2018: €5451
Adj net operating
free cash flow growth
+ 47%2
versus 20181
Innovation Sales
21%
ambition ~20%
Net
Profit
€764m
2018: €1,0793
Net
Earnings
€4.27
2018: €6.103
Adj Net
Earnings
€4.64
2018: €5.84
Proposed Dividend4
€2.40
2017: €1.85
1) Excludng temporary vitamin effect in 2018 of €415 million sales and €290 million (Adjusted) EBITDA.
2) Including the impact of IFRS 16.
3) 2018 includes the temporary vitamin effect and the book profit on the sale of DSM Sinochem Pharmaceuticals.
4) Subject to approval by the Annual General Meeting of Shareholders.
Latest financial & regulatory news
-
-
DSM announces results of 2020 Annual General Meeting of Shareholders
DSM held a virtual Annual General Meeting of Shareholders on 8 May 2020 when shareholders approved all resolutions on the agenda.
08 May 2020
-
DSM reports Q1 2020 results
DSM reports a solid Q1 2020, suspends overall earnings outlook given current limited visibility in Materials.
07 May 2020
Leadership team
Geraldine Matchett
Co-CEO & Member of the Managing Board
Geraldine Matchett (1972, British; French; Swiss) is Co-Chief Executive Officer & Chief Financial Officer and Member of the Managing Board of Royal DSM. She was appointed as Co-CEO on 15 February 2020. Geraldine joined DSM’s Managing Board in August 2014 and became CFO on 1 December 2014. Her current term will end in 2022.
Dimitri de Vreeze
Co-CEO & Member of the Managing Board
Dimitri de Vreeze is Co-Chief Executive Officer & Chief Operating Officer and Member of the Managing Board of Royal DSM. He was appointed as Co-CEO on 15 February 2020 and joined DSM’s Managing Board in 2013. His current term will end in 2021.
- gm
- ddv
Read more
-
Why invest in DSM
DSM is positioned to drive continued above market organic growth and deliver further improvement in profitability, shareholder return and sustainability as we execute Strategy 2021.
-
Factbooks
An introduction for investors and analysts to DSM, our Nutrition, Materials and Innovation Center clusters and our businesses.
-
Share performance
DSM's share performance in real time and historically.